Cel Sci Corp financial data

Symbol
CVM on NYSE
Industry
Biological Products, (No Diagnostic Substances)
Location
8229 Boone Blvd ., Suite 802, Vienna, Virginia
State of incorporation
Colorado
Fiscal year end
September 30
Latest financial report
Q1 2024 - May 15, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 141 % -70.5%
Debt-to-equity 121 % +96.7%
Return On Equity -218 % -87%
Return On Assets -98.5 % -36.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 54.2 M shares +21.1%
Common Stock, Shares, Outstanding 54.1 M shares +23.5%
Entity Public Float 97.6 M USD -83.6%
Common Stock, Value, Issued 541 K USD +23.5%
Weighted Average Number of Shares Outstanding, Basic 43.4 M shares +0.84%
Weighted Average Number of Shares Outstanding, Diluted 44.4 M shares +3.15%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 20 M USD -17.5%
General and Administrative Expense 9.23 M USD -0.38%
Operating Income (Loss) -29.2 M USD +12.8%
Net Income (Loss) Attributable to Parent -30 M USD +12.7%
Earnings Per Share, Basic -0.18 USD/shares +10%
Earnings Per Share, Diluted -0.85 USD/shares +4.49%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 5.14 M USD -81.7%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Inventory, Net 2.35 M USD
Assets, Current 8.51 M USD -32.3%
Property, Plant and Equipment, Net 9.11 M USD -18.5%
Operating Lease, Right-of-Use Asset 1.6 M USD -10.8%
Assets 30 M USD -21.3%
Accounts Payable, Current 1.02 M USD -46.2%
Accrued Liabilities, Current 1.22 M USD +14.6%
Liabilities, Current 5.09 M USD -4.24%
Operating Lease, Liability, Noncurrent 1.54 M USD -12%
Other Liabilities, Noncurrent 125 K USD 0%
Liabilities 15.7 M USD -12.8%
Retained Earnings (Accumulated Deficit) -501 M USD -6.36%
Stockholders' Equity Attributable to Parent 14.3 M USD -29%
Liabilities and Equity 30 M USD -21.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.89 M USD -4.74%
Net Cash Provided by (Used in) Financing Activities 4.05 M USD +6089%
Net Cash Provided by (Used in) Investing Activities -64.9 K USD -21.1%
Common Stock, Shares Authorized 600 M shares 0%
Common Stock, Shares, Issued 54.1 M shares +23.5%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 5.31 M USD -47.2%
Interest Paid, Excluding Capitalized Interest, Operating Activities 245 K USD -11.9%
Deferred Tax Assets, Valuation Allowance 60 M USD +13.3%
Deferred Tax Assets, Gross 62.7 M USD +11.5%
Operating Lease, Liability 1.76 M USD +824%
Payments to Acquire Property, Plant, and Equipment 51.7 K USD -3.6%
Lessee, Operating Lease, Liability, to be Paid 2.44 M USD
Property, Plant and Equipment, Gross 18.1 M USD +2.22%
Operating Lease, Liability, Current 211 K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 287 K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 366 K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure -9.8%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 680 K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 277 K USD
Deferred Tax Assets, Operating Loss Carryforwards 30.8 M USD +21.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 200 K shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 285 K USD
Operating Lease, Payments 85 K USD +28.8%
Additional Paid in Capital 515 M USD +4.89%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 8 K USD -20%
Deferred Tax Assets, Net of Valuation Allowance 60 M USD +13.3%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%